Insulet — Nov 7, 2024 release

4 2024 Outlook: Revenue Guidance (in constant currency): • For the year ending December 31, 2024, the Company is raising its expected revenue growth to a range of 20% to 21% (previously 16% to 19%). Revenue growth ranges by product line are: ◦ Total Omnipod of 21% to 22% (previously 18% to 21%) ▪ U.S. Omnipod of 19% to 21% (previously 18% to 21%) ▪ International Omnipod of 25% to 27% (previously 18% to 21%) ◦ Drug Delivery of (10)% to (5)% (previously (50)% to (40)%) • For the quarter ending December 31, 2024, the Company expects revenue growth of 12% to 15%. Revenue growth ranges by product line are: ◦ Total Omnipod of 13% to 16% ▪ U.S. Omnipod of 9% to 12% 5 ▪ International Omnipod of 30% to 33% ◦ Drug Delivery of (20)% to (15)% (app roximately $7 million to $8 million) Gross Margin and Operating Margin Guidance: For the year ending December 31, 2024 , the Company now expects gross margin to be approximately 69% (previously 68% to 69%, closer to the high end). For the year ending December 31, 2024, the Company is raising its expected operating margin by 50 basis points to approximately 14.5% . Conference Call: Insulet will host a conference call at 4:30 p.m. (Eastern Time) on November 7, 2024 to discuss the financial results and outlook. The link to the live call will be available on the Investor Relations section of the Company’s website at investors.insulet.com, “Events and Presentations,” and will be archived for future reference. The live ca